T
The startup develops a healthcare technology that identifies drug candidates capable of crossing the blood-brain barrier through the MFSD2A transporter protein. This technology enables the creation of selective drug molecules aimed at treating serious neurological diseases, improving patient outcomes.
Singapore, Singapore
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a healthcare technology that identifies drug candidates capable of crossing the blood-brain barrier through the MFSD2A transporter protein. This technology enables the creation of selective drug molecules aimed at treating serious neurological diseases, improving patient outcomes.